Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.57% | 81.09% | 275.96% | 130.61% | -9.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.16% | 9.41% | 1,363.66% | 56.03% | 34.09% |
| Operating Income | 6.16% | -9.41% | -1,363.66% | -56.03% | -34.09% |
| Income Before Tax | -554.65% | 62.39% | -626.88% | -59.73% | 89.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -554.65% | 62.39% | -626.88% | -59.73% | 89.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -554.65% | 62.39% | -626.88% | -59.73% | 89.64% |
| EBIT | 6.16% | -9.41% | -1,363.66% | -56.03% | -34.09% |
| EBITDA | 3.47% | -9.81% | -1,413.39% | -56.45% | -31.21% |
| EPS Basic | -546.03% | 64.70% | -772.66% | 99.26% | 99.95% |
| Normalized Basic EPS | -677.50% | 56.87% | -6,825.00% | 99.26% | 99.94% |
| EPS Diluted | -546.03% | 64.70% | -775.78% | 99.26% | 99.95% |
| Normalized Diluted EPS | -677.50% | 56.87% | -6,825.00% | 99.26% | 99.94% |
| Average Basic Shares Outstanding | 1.81% | 6.57% | -21.85% | 21,420.10% | 21,107.39% |
| Average Diluted Shares Outstanding | 1.81% | 6.57% | -21.85% | 21,420.10% | 21,107.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |